Equities Analysts Set Expectations for MediWound Q1 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Equities researchers at HC Wainwright dropped their Q1 2025 earnings per share estimates for MediWound in a research note issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their previous estimate of ($0.56). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound’s Q2 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at $0.80 EPS.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23. The business had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the firm earned ($0.19) EPS.

Several other analysts have also recently weighed in on the stock. Craig Hallum initiated coverage on shares of MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 price target for the company. StockNews.com upgraded MediWound to a “sell” rating in a research report on Friday.

MediWound Trading Up 1.1 %

MediWound stock opened at $16.45 on Monday. The company has a 50-day moving average price of $18.13 and a 200 day moving average price of $17.59. MediWound has a 12-month low of $12.78 and a 12-month high of $24.00. The stock has a market cap of $177.54 million, a P/E ratio of -5.67 and a beta of 0.82.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. R Squared Ltd purchased a new stake in shares of MediWound in the 4th quarter valued at approximately $32,000. Russell Investments Group Ltd. increased its holdings in MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,162 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in MediWound in the third quarter valued at approximately $89,000. Bank of America Corp DE lifted its stake in MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,178 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.